Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels
Expected to enroll 415 participants; interim results expected in Q3 2021
In parallel, preclinical studies are underway to evaluate additional mRNA candidates against emerging SARS-CoV-2 variants
PARIS and LEXINGTON, MASS. - March 12, 2021 - Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. The Companies expect interim results from this trial in the third quarter of 2021.
Sanofi and Translate Bio Initiate Phase 1/2 Clinical Trial of mRNA COVID-19 Vaccine Candidate marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Translate Bio Announces Departure of Chief Financial Officer
LEXINGTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, announced today that John Schroer, the Company’s Chief Financial Officer (CFO), is departing the Company for personal reasons. Mr. Schroer’s departure will be effective by year-end 2020. Robert Prentiss, Translate Bio’s Vice President and Corporate Controller since 2017, will serve as Principal Accounting Officer and report directly to the Company’s Chief Executive Officer, Ronald Renaud, on an interim basis while a formal search process to appoint a new CFO is conducted.